How will you change the future of Crohn’s disease?
About the Study
This clinical study is testing a novel approach for treatment of Crohn’s disease: treating the bacteria, Mycobacterium avium subsp. paratuberculosis (MAP), which may be a cause of Crohn's disease. This study is called MAP US.
This study will randomize 270 participants and take place in approximately 120 doctors’ offices in the US, and in Canada, Israel, Australia, New Zealand, and Poland. The study will involve participation of up to 62 weeks.
MAP US is designed to evaluate the effectiveness and safety of the study medication compared to placebo while participants remain on their Crohn’s disease medications.
The study medication is a combination of three antibiotics: clarithromycin, rifabutin, and clofazimine and is in pill form.
Remission at week 26 is the primary objective of MAP US; however, as MAP grows slowly, the duration of the study medication needed to achieve remission may vary.
In order to participate, you must be diagnosed with Crohn’s disease for longer than six months and be 18 to 75 years old.
Other criteria apply.
Study participants will receive study related exams, lab tests and study medication at no charge. Compensation is available.